

VARNAVAS HADJIPANAYIS LTD (representing Novo Nordisk) 2020

Date of publication: 30/06/2021

	Full Name <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Art. 3)</i>	Country of Principal Practice <i>(Schedule 1)</i>	Principal Practice Address <i>(Art. 3)</i>	Unique country identifier <i>OPTIONAL</i> <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b & 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c & 3.01.2.c)</i>		TOTAL <i>OPTIONAL</i>	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>													
HCPs	Dr. Polykarpos Evrpidou	Limassol	Cyprus	29 Vasileos Konstantinou 3075		N/A	N/A	0 €	0 €	520 €	150 €	670 €	
	Dr. Stelia Kadis	Nicosia	Cyprus	55-57 Andrea Avraamidi st, Strovolos		N/A	N/A	0 €	0 €	520 €	0 €	520 €	
	Dr. Marios Michael	Limassol	Cyprus	12 Nafpliou, 3025		N/A	N/A	160 €	0 €	0 €	0 €	160 €	
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						N/A	N/A	0 €	0 €	0 €	0 €	0 €	
Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>						N/A	N/A	0	0	0	0	Optional	
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>						N/A	N/A	0%	0%	0%	0%	N/A	
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>													
HCOs	Cyprus Society for the Study of Diabetes	Limassol	Cyprus	3 Pekinou Street, 3021				5,000 €				5,000 €	
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						0 €	0 €	0 €	0 €	0 €	0 €	Optional
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>						0	0	0	0	0	0	Optional
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>						%	%	%	%	%	%	N/A	
R & D	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined - <i>Article 3.04 and Schedule 1</i>											TOTAL AMOUNT	OPTIONAL